Major

2022 - 8 - 15

Post cover
Image courtesy of "Labiotech.eu"

Approval for Small Pharma major depressive disorder trial (Labiotech.eu)

Small Pharma has received approval from the U.K.'s MHRA to initiate a drug interaction clinical trial in the U.K..

“Encouraging results from this study could facilitate patient recruitment in future clinical trials as patients may no longer be required to discontinue their SSRI medication. Carol Routledge, chief medical and scientific officer, said: “In the phase I/IIa SPL026 clinical trial currently under way, patients must be withdrawn from existing antidepressant medication, which can be disruptive and unsettling for some. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects.

Tamil Nadu emerges as major base for electronic manufacturing ... (The Hindu)

As part of China+1 strategy, India is positioning itself as an alternate manufacturing destination from where global MNCs mainly from the U.S. can source.

Wearables/Hearables’ EMS business is estimated to grow from ₹200 crore in FY22 to ₹2,000 crore by FY26. and Telecom and Networking Products’ EMS business is estimated to grow from ₹5,700 crore in FY22 to ₹10,900 crore by FY26 at a CAGR of 17.8%. While the IT Hardware EMS business is estimated to grow from ₹4,500 crore in FY22 to ₹31,400 crore by FY26 at a CAGR of 62.6%, the Mechanics’ EMS business is estimated to grow from ₹2,000 crore in FY22 to . ₹6,400 crore by FY26 at a CAGR of 33.3% as per Frost & Sullivan research. The F&S report states that PLI scheme is expected to result in an increase in production of approximately $520 billion over the next five years. Televisions’ EMS business is estimated to grow from ₹6,300 crore in FY22 to ₹18,600 crore by FY26 at CAGR of 30.9%. Electric Vehicles‘ EMS business in India is estimated to grow from ₹600 crore in FY22 to ₹7,600 crore by FY26 at CAGR of 86.8%. The EMS market size for mobile phones is estimated to grow from ₹91,200 crore in FY22 to ₹2,72,300 crore by FY26 at a CAGR of 31.5% as per Frost & Sullivan research.

Explore the last week